WO2017222362A1 - 99mtc-edda/hynic-ipsma como un radiofármaco para la detección de la sobre-expresión del antigeno prostático de membrana - Google Patents
99mtc-edda/hynic-ipsma como un radiofármaco para la detección de la sobre-expresión del antigeno prostático de membrana Download PDFInfo
- Publication number
- WO2017222362A1 WO2017222362A1 PCT/MX2017/000068 MX2017000068W WO2017222362A1 WO 2017222362 A1 WO2017222362 A1 WO 2017222362A1 MX 2017000068 W MX2017000068 W MX 2017000068W WO 2017222362 A1 WO2017222362 A1 WO 2017222362A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hynic
- radiopharmaceutical
- psma
- prostate
- edda
- Prior art date
Links
- 239000012217 radiopharmaceutical Substances 0.000 title claims abstract description 26
- 229940121896 radiopharmaceutical Drugs 0.000 title claims abstract description 26
- 230000002799 radiopharmaceutical effect Effects 0.000 title claims abstract description 26
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title abstract description 36
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title abstract description 34
- 230000002018 overexpression Effects 0.000 title abstract description 3
- 239000000126 substance Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract description 28
- 206010028980 Neoplasm Diseases 0.000 abstract description 19
- KOUZWQLNUJWNIA-UHFFFAOYSA-N 2-hydrazinylpyridine-3-carboxamide Chemical compound NNC1=NC=CC=C1C(N)=O KOUZWQLNUJWNIA-UHFFFAOYSA-N 0.000 abstract description 14
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 14
- 238000002603 single-photon emission computed tomography Methods 0.000 abstract description 14
- 206010060862 Prostate cancer Diseases 0.000 abstract description 13
- IFQUWYZCAGRUJN-UHFFFAOYSA-N ethylenediaminediacetic acid Chemical compound OC(=O)CNCCNCC(O)=O IFQUWYZCAGRUJN-UHFFFAOYSA-N 0.000 abstract description 7
- 230000035945 sensitivity Effects 0.000 abstract description 7
- 230000002209 hydrophobic effect Effects 0.000 abstract description 6
- 238000003384 imaging method Methods 0.000 abstract description 6
- 238000001514 detection method Methods 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000009206 nuclear medicine Methods 0.000 abstract description 5
- 239000002738 chelating agent Substances 0.000 abstract description 3
- 125000003636 chemical group Chemical group 0.000 abstract description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 description 13
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 206010027476 Metastases Diseases 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- 206010061289 metastatic neoplasm Diseases 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- LHCIROHUTQLZCZ-UHFFFAOYSA-N 10-(4-aminobutyl)-19-[(2-amino-3-phenylpropanoyl)amino]-n-(1,3-dihydroxybutan-2-yl)-7-(1-hydroxyethyl)-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxamide Chemical compound O=C1NC(CC=2C=CC(O)=CC=2)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(CO)C(O)C)CSSCC1NC(=O)C(N)CC1=CC=CC=C1 LHCIROHUTQLZCZ-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- WJBPMDZACHSXSD-HLAGHTPDSA-N C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)c2ccc(NN)nc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 Chemical compound C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)c2ccc(NN)nc2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 WJBPMDZACHSXSD-HLAGHTPDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101000577424 Homo sapiens Proteasome subunit alpha type-4 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108010037516 PSMA-617 Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102100028813 Proteasome subunit alpha type-4 Human genes 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- OASZCUUPKKGVSG-UHFFFAOYSA-N [O].NC(O)=N Chemical compound [O].NC(O)=N OASZCUUPKKGVSG-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- AEBYHKKMCWUMKX-LNTZDJBBSA-K gallium (68Ga) gozetotide Chemical compound [68Ga+3].OC(=O)CC[C@@H](C(O)=O)NC(=O)N[C@H](C(O)=O)CCCCNC(=O)CCCCCNC(=O)CCC1=CC=C(O)C(CN(CCN(CC([O-])=O)CC=2C(=CC=C(CCC([O-])=O)C=2)O)CC([O-])=O)=C1 AEBYHKKMCWUMKX-LNTZDJBBSA-K 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000012633 nuclear imaging Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- JBHPLHATEXGMQR-LFWIOBPJSA-N vipivotide tetraxetan Chemical compound OC(=O)CC[C@H](NC(=O)N[C@@H](CCCCNC(=O)[C@H](CC1=CC=C2C=CC=CC2=C1)NC(=O)[C@H]1CC[C@H](CNC(=O)CN2CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC2)CC1)C(O)=O)C(O)=O JBHPLHATEXGMQR-LFWIOBPJSA-N 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Definitions
- the present invention relates to a new radiopharmaceutical inhibitor of! membrane-specific prosthetic antigen (IPSMA) containing hydrazinonicotinamide (HYNIC) as a critical chemical group in e! increase in lipophilicity of the molecule for e! coupling to the hydrophobic sites of the PSMA » combined with the conventional use of HYNIC as a chelating agent for the 99m Tc radiometal, where ethylenediamine diacetic acid (EDDA) is used to complete the radiometal coordination sphere.
- IPSMA radiopharmaceutical inhibitor of! membrane-specific prosthetic antigen
- HYNIC hydrazinonicotinamide
- the new 99m Tc-EDDA / HYNIC ⁇ iPSIvIA radiopharmaceutical detects, with high affinity in vivo, the PSMA protein overexpressed in prostate cancer cells using SPECT molecular imaging techniques in nuclear medicine,
- BACKGROUND Prostate cancer is e! second most common cancer in men worldwide [Jemal A, et al. Cancer statlstics, 2Q10. CA Cancer J Clin. 201Q, 60: 277-300], In patients with localized PCa, the five-year survival rate is close to 100%; however, in patients with metastases, the survival rate at five years is 31% [Wei Q. er a /. Global ana ⁇ ysis heard ⁇ sfferentially expmssed genes in androg & n-independent prostate cancer. Prostate Cancer Prostatic Dis. 2007, 10: 167 ⁇ -174 ⁇ . Almost all patients with metastases respond well to anti-androgen treatments. However, the main cause of death in patients with PCa is the progression to androgen independence.
- PSMA membrane-specific prostate antigen
- the PSMA gene is composed of 19 exons that span - 60 kb of genomic DNA. This gene encodes a transmembrane type II protein! with short ctoptasmatic fragment (19 amino acid), a hydrophobic transmembrane domain (24 amino acids), and a large extracellular domain (707 amino acids).
- PSMA contains Zn in the active center of the enzyme, so the sequence Glu ⁇ hH-CO-NH-Lys (p-naphthyl alanine and Glu-Urea-LystNal), has been proposed as an effective inhibitor of its activity [ Beneaová, M, et el.
- radiopharmaceutical coughs of PSMA can also be used in another unit of neoplasms other than CaP, as in the case of mestatic breast cancer, osteosarcomas, gltomas and thyroid cancer, among others [Fougere, et al. In vivo visualization of prostate-sped ⁇ c antigen membrane In güoblastoma. Eur J Nud Med and Molglig, 2015, 42: 170-171; Verburg FA, et al.
- the uptake of the radiopharmaceutical in tumors or their metastases should be evaluated by nuclear imaging to confirm whether or not the treatment will be useful for the patient, as well as to determine the activity necessary to administer to impart the dose of abtotive radiation to cough tumors, that is, personalized medicine is practiced. It is therefore necessary to use radlottrmacos day nosis g Inhibldoff- PSMA in order to obtain molecular imaging tornograffa emission tomography (PET) or photon emission tomograffa ⁇ nk »(SPECT).
- PET molecular imaging tornograffa emission tomography
- SPECT photon emission tomograffa ⁇ nk »
- PET is the one with the highest spatial resolution and sensitivity, so most of the iadiof & maco8 commercial PSMA inhibitor diagnoses have been developed based on * Ga, which is a radionuclide for PET [ Eder M et al. Novel predlnlcal and radtopharmaceut ⁇ cal spice of [68Ga] Ga-PSMA-HBED-CC; a naw PET trocar fot Imaglng of prostate cancar. PharmaceutfcaJs, 2014, 7: 779-796; Eder M et al.
- a new InhbkJor radtofármaco of the membrane-specific prosthetic antigen (IPSMA) containing hk-razironicotinamide (HYNIC) is presented as a critical chemical group in the Increase of the HpofiVa of the molecule for coupling to the hydrophobic sites of PSMA , in addition to the conventional use of HYNIC as a chelating agent for the radometal "Te, where ethylenedylaminodiaoatic acid (EDDA) is used to complete the sphere of coordination of the radtometal.
- IPSMA membrane-specific prosthetic antigen
- HYNIC hk-razironicotinamide
- the new radiopharmaceutical of" ⁇ c-EDDA / HYNIC-iPSMA detects, with aria affinity In vivo, to the PSMA protein overexpressed in prostate cancer cells by SPECT molecular imaging techniques in nuclear medicine.
- Figure 1 shows schematically the structure of the radiopharmaceutical to be patented ( 99m Tc EDDA / HYNIC-IPSMA).
- HYNIC also functions as a spacer between the biological recognition site and the tomato radius, while in other radiophannacs, HYNIC uses exdueWaments as a bifunctonal agent for marking with "Te [ Decristofóro C et al "" ToEDDA / HYNIC-TOC: a new "" Tc-tebeHed radlopharmaceutlcal for Imagino somatoatatin receptor-positive tumours; f ⁇ rst cUnlcal result and Intra-patient oompar ⁇ son with i11 ln-labelhd octreotide N derivatives, 2000, J , 1318-26; Ferro-Flores G et al.
- the guHámk acid dUer-butfl ester was used, which was reacted with carbonyldiimidazole (CDI) in the presence of triethylamine (TEA) to form the acylmidazole derivative, which was activated with motyl triflate ( MeOTT) to react with the (S) -er-butyl-2-amino-e- (beridloxlcarbonylamino) hexanoate (Cbz-Lys-Ot-Bu) with subsequent deprotection of the Cbz via hydrogenolysis, thus obtaining the Glu-Urea-Lys derivative , which was reacted in solid phase (MBHA resin) with the arnlnoóckk) Frnoo ⁇ -naphthyl alanine (HBTU / HOBt), followed by 6-Boc4ikjraztoopiridin-3- acid TABLE
- HYNIC-IPSMA (37.5 pg) was formulated as a lyophilized pharmaceutical form containing 10 mg of EDDA, 20 mg of tricine, 20 ug of stannous chloride and 50 mg of mantle.
- the radiopharmaceutical remains stable with a radiochemical purity greater than 95% after 24 h of labeling.
- Vital stability tests in human serum show a serum protein binding of 8.3 ⁇ 2.1% and high radiochemical stability (> 90%).
- the compound showed no toxicity or adverse effects when administered at a dose of 40 mg / kg in laboratory baJb-C mice.
- Blodlstribution tests of 99m Tc -ECX) A / HYNIC-IPSMA in athymic mice with LNCaP induced tumors, showed a tumor uptake of 8.7 ⁇ 1.3% of the activity administered per gram of tissue (% ID / g) with route of mainly renal elimination.
- Btokinetic and dosimetry tests in healthy volunteers show rapid blood clearance with greater renal uptake and excretion, lower hepatic uptake and high uptake in parathyroid, salivary and lacrimal glands, with an average effective dose of 4 ⁇ 2 mSv per 740 MBq managed.
- Figure 4 shows a SPECT image of the 99m Tc-EDDA / HYNIC-IPSMA radiopharmaceutical obtained in a healthy volunteer.
- Flguni 5 shows a SPECT image of the 99m Tc-EDDA / HYNIC-IPSMA radbharmaceutical obtained in a patient with prostate cancer, confirming the ability of the radiopharmaceutical to detect in vivo PSMA over-expressed in prostate cancer cells.
- FIG. 6 shows the PET and SPECT image of the same patient with advanced metastatic prostate cancer who was given both 68 Ga-PSMAr617 (PET) and "Tc-EDDA / HYNIC-iPSMA (SPECT), showing that both radiopharmaceuticals Highly sensitive tumors and prostate cancer metastases associated with the recognition of PSMA overexpression are detected
- PET 68 Ga-PSMAr617
- SPECT positron emission tomography
- This image confirms and is the main evidence that due to its affinity properties Increased by the Itpofllia of the incorporated molecule of HYNIC, 99m Tc-EDDA / HYNIC-fPSMA is able to match the high image sensitivity of PET radionuclides in the detection of tumor lesions that overexpress PSMA.
- the 99m Tc-EDDA / HYNIC-IPSMA is obtained with the following characteristics:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201892668A EA201892668A1 (ru) | 2016-06-24 | 2017-06-21 | Tc-EDDA/HYNIC-iPSMA В КАЧЕСТВЕ РАДИОФАРМАЦЕВТИЧЕСКОГО ПРЕПАРАТА ДЛЯ ОБНАРУЖЕНИЯ СВЕРХЭКСПРЕССИИ ПРОСТАТСПЕЦИФИЧЕСКОГО МЕМБРАННОГО АНТИГЕНА |
DK17815772.3T DK3486249T3 (da) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma som et radiofarmaceutisk middel til detektering af overekspressionen af prostata-specifikt membranantigen |
ES17815772T ES2906332T3 (es) | 2016-06-24 | 2017-06-21 | 99MTc-EDDA/HYNIC-iPSMA como un radiofármaco para detectar la sobreexpresión de antígeno prostático específico de membrana |
CA3059545A CA3059545C (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
BR112018076593-7A BR112018076593B1 (pt) | 2016-06-24 | 2017-06-21 | Composto para radiomarcação, composto radiofarmacêutica, e composição radiofarmacêutica |
EP21205156.9A EP4083049A3 (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
CN201780049494.4A CN109641924B (zh) | 2016-06-24 | 2017-06-21 | 作为检测前列腺特异性膜抗原的过表达的放射性药物的99mtc-edda/hynic-ipsma |
EP17815772.3A EP3486249B1 (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
PL17815772T PL3486249T3 (pl) | 2016-06-24 | 2017-06-21 | 99mTc-EDDA/HYNIC-IPSMA JAKO RADIOFARMACEUTYK DO WYKRYWANIA NADEKSPRESJI ANTYGENU BŁONOWEGO SWOISTEGO DLA PROSTATY |
US16/310,744 US10918745B2 (en) | 2016-06-24 | 2017-06-21 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate specific membrane antigen |
ZA2018/07828A ZA201807828B (en) | 2016-06-24 | 2018-11-20 | 99m tc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
US17/135,424 US11547767B2 (en) | 2016-06-24 | 2020-12-28 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXMX/A/2016/008466 | 2016-06-24 | ||
MX2016008466A MX2016008466A (es) | 2016-06-24 | 2016-06-24 | 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana. |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/310,744 A-371-Of-International US10918745B2 (en) | 2016-06-24 | 2017-06-21 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate specific membrane antigen |
EP21205156.9A Previously-Filed-Application EP4083049A3 (en) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
US17/135,424 Continuation US11547767B2 (en) | 2016-06-24 | 2020-12-28 | 99mTc-EDDA/HYNIC-iPSMA as a radiopharmaceutical for detecting the overexpression of prostate-specific membrane antigen |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017222362A1 true WO2017222362A1 (es) | 2017-12-28 |
Family
ID=60783979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2017/000068 WO2017222362A1 (es) | 2016-06-24 | 2017-06-21 | 99mtc-edda/hynic-ipsma como un radiofármaco para la detección de la sobre-expresión del antigeno prostático de membrana |
Country Status (15)
Country | Link |
---|---|
US (2) | US10918745B2 (es) |
EP (2) | EP3486249B1 (es) |
CN (1) | CN109641924B (es) |
BR (1) | BR112018076593B1 (es) |
CA (1) | CA3059545C (es) |
DK (1) | DK3486249T3 (es) |
EA (1) | EA201892668A1 (es) |
ES (1) | ES2906332T3 (es) |
HU (1) | HUE057891T2 (es) |
MA (1) | MA45687A (es) |
MX (1) | MX2016008466A (es) |
PL (1) | PL3486249T3 (es) |
PT (1) | PT3486249T (es) |
WO (1) | WO2017222362A1 (es) |
ZA (1) | ZA201807828B (es) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019177449A1 (es) | 2018-03-14 | 2019-09-19 | Instituto Nacional De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana |
EP3721907A1 (en) | 2019-04-12 | 2020-10-14 | Narodowe Centrum Badan Jadrowych, Osrodek Radioizotopow POLATOM | Psma inhibitor derivatives for labelling with 99mtc via hynic, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics |
WO2022253785A2 (en) | 2021-05-31 | 2022-12-08 | Universität Heidelberg | Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111233758B (zh) * | 2020-03-02 | 2021-04-23 | 北京大学第一医院 | 一种psma抑制剂及其应用和靶向psma的核素成像试剂 |
CN111253465A (zh) * | 2020-03-03 | 2020-06-09 | 复旦大学附属肿瘤医院 | 一种psma结合剂及其用途 |
IL297423A (en) * | 2020-04-24 | 2022-12-01 | Radiomedix Inc | The composition, kit and method for the diagnosis and treatment of prostate cancer |
MX2021005089A (es) * | 2021-04-30 | 2022-11-01 | Instituto Nac De Investigaciones Nucleares | Radiofarmacos basados en el acido ((r)-1-((6-hidrazinilnicotinoil) d-alanil)pirrolidin-2-il)boronico (hynic-ifap) para la deteccion de la sobreexpresion de la proteina de activacion de fibrolastos. |
EP4400505A1 (en) * | 2021-09-03 | 2024-07-17 | Bivision Pharmaceuticals, Inc | Peptide-urea derivative, pharmaceutical composition containing same and application thereof |
CN114569744A (zh) * | 2022-03-08 | 2022-06-03 | 安徽淮仁堂药业股份有限公司 | 一种锝前列腺标特异性膜抗原显像剂试剂盒及其制备方法和应用 |
CN115260155B (zh) * | 2022-08-08 | 2023-11-10 | 北京师范大学 | 一种含三唑环和肼基尼古酰胺基的谷氨酸-脲衍生物及其应用 |
CN117434270B (zh) * | 2023-09-11 | 2024-05-07 | 江苏省人民医院(南京医科大学第一附属医院) | 一种可携带放射性信号的蛋白质支架及其抗体检测中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009002529A2 (en) * | 2007-06-26 | 2008-12-31 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
MX2010003830A (es) * | 2010-04-08 | 2011-10-31 | Inst Nac De Investigaciones Nucleares | 99mtc-edda/hynic-ggc-aunp-manosa como un nuevo radiofarmaco para la deteccion del ganglio centinela en cancer de mama. |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102949735B (zh) | 2011-08-30 | 2015-06-10 | 北京大基康明医疗设备有限公司 | 放射性药物的制备方法及系统 |
ES2725314T3 (es) | 2012-04-10 | 2019-09-23 | Lantheus Medical Imaging Inc | Métodos de síntesis radiofarmacéutica |
WO2016062370A1 (en) * | 2014-10-20 | 2016-04-28 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
-
2016
- 2016-06-24 MX MX2016008466A patent/MX2016008466A/es unknown
-
2017
- 2017-06-21 CA CA3059545A patent/CA3059545C/en active Active
- 2017-06-21 PT PT178157723T patent/PT3486249T/pt unknown
- 2017-06-21 CN CN201780049494.4A patent/CN109641924B/zh active Active
- 2017-06-21 US US16/310,744 patent/US10918745B2/en active Active
- 2017-06-21 ES ES17815772T patent/ES2906332T3/es active Active
- 2017-06-21 PL PL17815772T patent/PL3486249T3/pl unknown
- 2017-06-21 HU HUE17815772A patent/HUE057891T2/hu unknown
- 2017-06-21 WO PCT/MX2017/000068 patent/WO2017222362A1/es unknown
- 2017-06-21 EA EA201892668A patent/EA201892668A1/ru unknown
- 2017-06-21 DK DK17815772.3T patent/DK3486249T3/da active
- 2017-06-21 EP EP17815772.3A patent/EP3486249B1/en active Active
- 2017-06-21 MA MA045687A patent/MA45687A/fr unknown
- 2017-06-21 BR BR112018076593-7A patent/BR112018076593B1/pt active IP Right Grant
- 2017-06-21 EP EP21205156.9A patent/EP4083049A3/en active Pending
-
2018
- 2018-11-20 ZA ZA2018/07828A patent/ZA201807828B/en unknown
-
2020
- 2020-12-28 US US17/135,424 patent/US11547767B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009002529A2 (en) * | 2007-06-26 | 2008-12-31 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
MX2010003830A (es) * | 2010-04-08 | 2011-10-31 | Inst Nac De Investigaciones Nucleares | 99mtc-edda/hynic-ggc-aunp-manosa como un nuevo radiofarmaco para la deteccion del ganglio centinela en cancer de mama. |
Non-Patent Citations (2)
Title |
---|
S M HILLIER ET AL.: "99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer", JOURNAL OF NUCLEAR MEDICINE, vol. 54, no. 8, 1 August 2013 (2013-08-01), pages 1369 - 1371, XP055280729 * |
See also references of EP3486249A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019177449A1 (es) | 2018-03-14 | 2019-09-19 | Instituto Nacional De Investigaciones Nucleares | 177lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana |
EP3766893A4 (en) * | 2018-03-14 | 2022-02-16 | Instituto Nacional de Investigaciones Nucleares | 177LU-DOTA-HYNIC-IPSMA USED AS A THERAPEUTIC RADIOPHARMACEUTICAL PRODUCT DIRECTED AGAINST PROSTATE MEMBRANE SPECIFIC ANTIGEN |
EP3721907A1 (en) | 2019-04-12 | 2020-10-14 | Narodowe Centrum Badan Jadrowych, Osrodek Radioizotopow POLATOM | Psma inhibitor derivatives for labelling with 99mtc via hynic, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics |
WO2022253785A2 (en) | 2021-05-31 | 2022-12-08 | Universität Heidelberg | Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
US11547767B2 (en) | 2023-01-10 |
US20190343970A1 (en) | 2019-11-14 |
PT3486249T (pt) | 2022-02-02 |
US20210187132A1 (en) | 2021-06-24 |
ZA201807828B (en) | 2021-03-31 |
US10918745B2 (en) | 2021-02-16 |
CA3059545C (en) | 2021-07-27 |
CA3059545A1 (en) | 2017-12-28 |
CN109641924A (zh) | 2019-04-16 |
PL3486249T3 (pl) | 2022-05-23 |
EP4083049A3 (en) | 2022-12-21 |
ES2906332T3 (es) | 2022-04-18 |
DK3486249T3 (da) | 2022-02-07 |
CN109641924B (zh) | 2022-02-25 |
EP4083049A2 (en) | 2022-11-02 |
MA45687A (fr) | 2021-03-31 |
BR112018076593A2 (pt) | 2019-04-16 |
BR112018076593B1 (pt) | 2022-05-24 |
HUE057891T2 (hu) | 2022-06-28 |
EP3486249B1 (en) | 2021-11-10 |
EA201892668A1 (ru) | 2019-10-31 |
MX2016008466A (es) | 2017-12-25 |
EP3486249A1 (en) | 2019-05-22 |
EP3486249A4 (en) | 2020-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017222362A1 (es) | 99mtc-edda/hynic-ipsma como un radiofármaco para la detección de la sobre-expresión del antigeno prostático de membrana | |
ES2960729T3 (es) | 177 Lu-dota-hynic-ipsma como un radiofármaco terapéutico dirigido al antígeno prostático específico de membrana | |
Ferro-Flores et al. | Clinical translation of a PSMA inhibitor for 99mTc-based SPECT | |
Ekblad et al. | Development and preclinical characterisation of 99m Tc-labelled Affibody molecules with reduced renal uptake | |
Maina et al. | Targeting prostate cancer with radiolabelled bombesins | |
Ortiz-Arzate et al. | Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c (RGDfK)] 2 for breast cancer imaging | |
CN107438615A (zh) | 用于制备放射性核素络合物的方法和试剂盒 | |
Cui et al. | Evaluation of 188Re-MAG2-RGD-bombesin for potential prostate cancer therapy | |
Larenkov et al. | Radionuclide diagnosis of prostate cancer: Positron emission tomography with 68Ga-PSMA inhibitors and their pharmaceutical development | |
Endepols et al. | Peripheral ganglia in healthy rats as target structures for the evaluation of PSMA imaging agents | |
Nock et al. | Theranostic perspectives in prostate cancer with the GRPR-antagonist NeoBOMB1–preclinical and first clinical results | |
Abouzayed et al. | 177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry | |
KR101646577B1 (ko) | 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물 | |
Zhang et al. | Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with 99mTc-Hynic-PEG-AE105 | |
Escudero | PSMA-inhibiting oncotheranostic radiopharmaceuticals for translational nuclear medicine | |
Hernández-Cairo et al. | Comparative Study of the Biodistribution of 99mTc-HYNIC-Lys3-Bombesin Obtained With the EDDA/Tricine and AN/Tricine as Coligands | |
Bouziotis et al. | Radiochemical and radiobiological assessment of a pyridyl-S-cysteine functionalized bombesin derivative labeled with the 99mTc (CO) 3+ core | |
Müller et al. | Folate Receptor-Targeted Radionuclide Imaging Agents | |
Lu | Development and evaluation of radioimaging agents targeting prostate-specific membrane antigen | |
EA040919B1 (ru) | 177Lu-DOTA-HYNIC-iPSMA В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО РАДИОФАРМАЦЕВТИЧЕСКОГО СРЕДСТВА, НАЦЕЛЕННОГО НА ПРОСТАТИЧЕСКИЙ СПЕЦИФИЧЕСКИЙ МЕМБРАННЫЙ АНТИГЕН | |
Liolios et al. | Bispecific PSMA-617/RM2 Heterodimer for Theranostics Applications in Prostate Cancer | |
Schweinsberg | Novel 99mTc-labeled bombesin analogues with improved pharmacokinetics for targeting of gastrin-releasing-peptide receptor-positive tumors | |
Aranda | Synthesis and radiolabelling of a hetero bivalent conjugate of bombesin and folic acid for the evaluation of the metabolic activity of breast cancer cells | |
EA040690B1 (ru) | 99mTc-EDDA/HYNIC-iPSMA В КАЧЕСТВЕ РАДИОФАРМАЦЕВТИЧЕСКОГО ПРЕПАРАТА ДЛЯ ОБНАРУЖЕНИЯ СВЕРХЭКСПРЕССИИ ПРОСТАТСПЕЦИФИЧЕСКОГО МЕМБРАННОГО АНТИГЕНА | |
Liu et al. | Evaluation of a novel Tc-99m-labeled HYNIC-conjugated lactam bridge-cyclized alpha-MSH peptide for human melanoma imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17815772 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018076593 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2017815772 Country of ref document: EP Effective date: 20190124 |
|
ENP | Entry into the national phase |
Ref document number: 112018076593 Country of ref document: BR Kind code of ref document: A2 Effective date: 20181219 |
|
ENP | Entry into the national phase |
Ref document number: 3059545 Country of ref document: CA |